Trial Search Results

Serial Ultrasound to Detect Early Response to Immunotherapy in Advanced Renal Cell Carcinoma

Primary objective is to assess whether changes in quantitative tumor perfusion parameters 3 weeks after start of treatment of renal cell carcinoma (RCC) patients with immune checkpoint inhibitor (ICI) therapy.

Secondary objectives are to evaluate if there is an optimal ultrasound imaging modality (conventional power Doppler or LEAD ultrasound or CEUS) or optimal time point to predict initial objective response

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Diagnostic Test: Doppler ultrasound
  • Diagnostic Test: Long Ensemble Angular-coherence Doppler [LEAD] ultrasound
  • Diagnostic Test: Contrast-enhanced ultrasound (CEUS)




Inclusion Criteria:

   - 18 years of age or older

   - pathology-confirmed diagnosis of RCC

   - at least one tumor lesion greater than 1 cm in diameter (in primary kidney site and/or
   in a metastatic site such as liver or adrenal gland), amenable to ultrasound imaging

   - planned to be treated with ipilimumab plus nivolumab or other ICI

   - written informed consent

Exclusion Criteria:

   - any comorbid condition that, in the opinion of the treating provider or the Protocol
   Directors, compromises the participant's ability to participate in the study (e.g.,
   compromised consent capacity)

   - hypersensitivity to sulfur hexafluoride lipid microsphere or its components, such as
   polyethylene glycol (PEG)

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christian Remy Hoerner